WEBINAR: Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay – 28 June 2023

cnb825 webinar promo v1 |
Learn more
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • CN Bio appoints Dr. Samantha Macro as Chief Financial Officer

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      View all news

      Upcoming Events

      • ISSX DMDG 2023

      • MPS World Summit Berlin 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Organ-on-a-Chip Resources

Resource type

Area of interest

Posters

Resource image

Modelling the intestine-liver axis: The role of FXR agonists in a multi-organ microphysiological system model of non-alcoholic fatty liver disease

Here, we demonstrate the potential of a liver and a gut/liver microphysiological systems (MPS) to recapitulate NAFLD and NASH phenotypes in vitro and explore the molecular mechanisms underlying the development of NAFLD/NASH as well as assess the efficacy of novel therapeutic strategies.

Webinars

Resource image

The Human Touch

Webinar Series 5 Episode 4

In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets.

Webinars

Resource image

The Dash for NASH

Webinar Series 5 Episode 3

Find out how to: rapidly adopt an organ-on-a-chip (OOC) approach to NASH research, generate clinically translatable data from an industry-proven in vitro NASH model, and how OOC can help you unlock NASH disease mechanisms, and confirm drug efficacy and safety.

Application notes

Resource image

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Kostrzewski et al

As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks.

Infographic

Resource image

Pros and cons of preclinical models of Non-Alcoholic Steatohepatitis

This infographic was made by Biotechniques to help educate people on our NASH-in-a-box kit and how it sets a new standard in the search for an approved NASH therapeutic.

Videos and animations

Resource image

In Focus: Modeling NASH disease – organ-on-a-chip technologies

This short animation describes how our NASH-in-a-box kit enhances your chance of successfully developing NASH therapeutics by recreating our industry-proven NASH model in your laboratory. Created by Biotechniques.

Podcasts

Resource image

Organ-on-a-Chip Models of Fatty Liver Disease

15-Minute Tech Blast – In this podcast developed by Biotechniques, our Lead Scientist Gareth Guenigault discussed NAFLD & NASH and their growing prevalence both in terms of cases and economic factors.

Articles

Resource image

New Model Will Support Drug Discovery for Liver Disease NASH

Dr Audrey Doubourg discusses the therapeutic challenges of NASH and how our NASH-in-a-box kit will help to advance drug discovery.

This article is taken from Technology Networks, April 2022.

Articles

Resource image

A pressing Need for Accurate Preclinical Models of Metabolic Disease

How using organ-on-a-chip (OOC) can more accurately recapitulate the physiology and functions of the human body by culturing under flow perfusion – to mimic the blood – in 3D.

This article is taken from European Biopharmaceutical Review January 2022, pages 28-31.

Scientific publications

Resource image

β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development

Rao et al., 2021

This study shows the effect of the presence of β2-spectrin (SPTBN1) in the promotion of sterol regulatory element (SRE)–binding protein (SREBP)–stimulated lipogenesis. These findings suggest SPTBN1 could be a potential target for a therapeutic against NASH and liver cancer.

Articles

Resource image

Hype or hope – microphysiological systems?

This article in DDW examines MPS (microphysiological systems/organ-on-a-chip) in drug discovery and their place in the preclinical ‘toolbox’.

This article is taken from Drug Discovery World, October 2021.

Scientific publications

Resource image

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system

Kostrzewski et al., 2021

It was shown in this study that the MPS NASH model, composed of a primary cell co-culture in various conditions, is able to model different characteristics of clinical NASH, including advanced disease with a quantifiable fibrosis phenotype as well as pharmaceutical intervention.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility | Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio appoints Dr. Samantha Macro as Chief Financial Officer June 6, 2023
  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023

Upcoming events

ISSX DMDG 2023 June 11-14, 2023

MPS World Summit Berlin 2023 June 26-30, 2023